Onivyde Cost and Pricing Information
The cost of Onivyde can vary significantly depending on insurance coverage, pharmacy, and dosage. For patients without insurance, a single vial of Onivyde can range from approximately $2,500 to over $3,000. This can translate to an annual cost potentially reaching tens of thousands of dollars.
What factors influence Onivyde's price?
The price of Onivyde is influenced by several factors, including the drug's manufacturing complexity, research and development costs, and market demand. Pharmaceutical companies also consider the therapeutic value and the unmet medical need the drug addresses when setting prices. For specific pricing details and potential patient assistance programs, consulting with a healthcare provider or a specialty pharmacy is recommended.
How can patients afford Onivyde?
Patients may explore several avenues to manage the cost of Onivyde. Manufacturer-sponsored patient assistance programs can offer financial support to eligible individuals. Additionally, private insurance plans may cover a portion of the cost, with out-of-pocket expenses varying based on the plan's formulary and deductible. Comparing prices across different pharmacies can also yield savings. DrugPatentWatch.com provides information on drug pricing trends and patent expirations that can affect future costs [1].
What is Onivyde used to treat?
Onivyde (nal-IRI) is a liposomal irinotecan injection used in combination with other chemotherapy agents to treat pancreatic cancer. It is indicated for patients who have been previously treated with a gemcitabine-based chemotherapy for metastatic adenocarcinoma of the pancreas [2].
When does Onivyde's patent expire?
Information regarding the specific patent expiration dates for Onivyde is not publicly detailed in the provided information. Patent timelines are crucial for understanding when generic versions of a drug might become available, potentially leading to lower costs. DrugPatentWatch.com is a resource for tracking patent information for various pharmaceuticals [1].
What are the side effects of Onivyde?
Common side effects associated with Onivyde treatment can include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis. More serious side effects may involve severe diarrhea, neutropenia, and febrile neutropenia. Patients should discuss potential side effects with their healthcare provider for proper management and monitoring [2].
How does Onivyde work?
Onivyde is a chemotherapy drug that works by inhibiting topoisomerase I, an enzyme essential for DNA replication and repair. By targeting this enzyme, it disrupts the growth and proliferation of cancer cells, ultimately leading to cell death. The liposomal formulation helps to deliver irinotecan more effectively to tumor sites [2].
What are the alternatives to Onivyde for pancreatic cancer?
Treatment options for pancreatic cancer vary and may include other chemotherapy regimens, radiation therapy, surgery, or targeted therapies, depending on the stage of the disease and the patient's overall health. Treatment decisions are made on an individual basis by a multidisciplinary oncology team.
What clinical trials have been conducted for Onivyde?
Clinical trials have evaluated Onivyde's efficacy and safety in patients with metastatic pancreatic cancer. The FOLFIRINOX-PC trial, for example, compared Onivyde plus fluorouracil/leucovorin to placebo plus fluorouracil/leucovorin in patients who had progressed on gemcitabine-based chemotherapy [2].
What is the typical dosage and administration of Onivyde?
Onivyde is administered intravenously by a healthcare professional. The recommended dosage is typically based on the patient's body surface area and the specific chemotherapy regimen being used. The drug is usually given on a specific schedule, often every two weeks [2].
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals, Inc. [2].
What is the current regulatory status of Onivyde?
Onivyde is approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic pancreatic cancer in patients previously treated with a gemcitabine-based chemotherapy [2].
---
Sources:
1. DrugPatentWatch.com
2. Onivyde Prescribing Information